The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K.
Radar 89 (high attention) · dilution pressure high · listing risk elevated · governance risk elevated · runway 0.9 mo · strongest signal: Runway < 6 months (Jun 30, 2026)
What would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
What would prove it wrong: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.
Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.
The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Cash need (going-concern language, runway < 6 months) coexists with live selling machinery (atm program, equity line, pipe, shelf effective, shelf filed, offering (424b)). Base case is a discounted raise; the question is when, not if.
Variable-priced paper is outstanding while the listing is under stress — the structure where dilution can accelerate. Watch the share count each quarter. Discount-priced or variable-priced securities are outstanding while the company is managing its listing with reverse splits/notices. Each conversion lowers the price, which lowers the next conversion price.
No note yet. Notes are written each morning for the top-ranked setups; Pro subscribers get them in full the same day.
Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 47 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.
Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.
| Date | Signal | Evidence | Score |
|---|---|---|---|
| Aug 14, 2026 | ▼ Going-concern language | “going concern periodic” language in 10-Q (10-Q) filed 2026-08-14 filing | 33 |
| Aug 13, 2026 | ▼ Equity line | “equity line” language in 8-K (EX-99.1) filed 2026-08-13 filing | 48 |
| Aug 13, 2026 | ▼ Offering (424B) | 424B4 prospectus supplement 2026-08-13; 2 prior 424B filings in 12m filing | 47 |
| Aug 13, 2026 | ▼ ATM program | “atm” language in 8-K (EX-4.1) filed 2026-08-13 filing | 38 |
| Aug 13, 2026 | ▼ PIPE | “pipe” language in 8-K (8-K) filed 2026-08-13 filing | 33 |
| Aug 13, 2026 | ▼ Reverse split | “reverse split” language in 8-K (EX-4.2) filed 2026-08-13 filing | 32 |
| Aug 12, 2026 | ▼ Shelf effective | EFFECT notice 2026-08-12 filing | 21 |
| Jul 28, 2026 | ▼ Shelf filed | S-1/A filed 2026-07-28 filing | 30 |
| Jul 24, 2026 | ▼ Holder rights modified | 8-K Item 3.03 filed 2026-07-24 (accepted 16:32 ET) filing | 33 |
| Jun 30, 2026 | ▼ Runway < 6 months | ~0.9 months runway: liquidity $141,831 as of 2026-06-30, burn $1,936,654/yr (annualized 180-day YTD operating cash flow [companyfacts]) filing | 49 |
| Jun 30, 2026 | ▼ Share count +25% | Shares outstanding 10,524,032 (2026-05-15) -> 14,450,323 (2026-08-14), +37% filing | 34 |
| Jun 30, 2026 | ▼ Near $5M MVLS floor | Public float $5,303,406 (as of 2025-06-30) vs $5M Nasdaq MVLS floor; needs price x shares confirmation filing | 26 |
| Jun 30, 2026 | ▼ Cash < current liabilities | Liquidity $141,831 vs current liabilities $4,376,884 filing | 21 |
VIVS VivoSim Labs, INC. · HCWB HCW Biologics Inc. · CYCU Cycurion, Inc. · BIAF bioAffinity Technologies, In · XHLD TEN Holdings, Inc. · VSEE VSEE HEALTH, INC. · screener →